Eton Pharmaceuticals, Inc.
ETONNasdaq
$42.32
↑ +13.8%Jul 17 close · end-of-day
Price
1Y↑ +204.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.3B
Enterprise Value
$1.3B
P/E
—
P/S
15.4
P/B
43.6
EV/EBITDA
217.1
PEG
—
FCF Yield
1.2%
Dividend Yield
—
Revenue (TTM)
$86.9M
Net Income (TTM)
-$1.5M
Free Cash Flow (TTM)
$15.4M
Gross Margin
54.8%
Operating Margin
2.4%
Net Margin
-1.7%
ROE
-4.8%
ROIC
3.9%
Debt / Equity
1.0
Net Cash
-$11.1M
Return 1Y
+203.4%
Company profile
Eton Pharmaceuticals, Inc. focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting from vasodilation in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age.
- CEO
- Sean E. Brynjelsen
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Illinois
- Website
- etonpharma.com
Management & directors
- Brynjelsen SeanPresident & CEO
- Krempa DavidChief Business Officer
- Gruber James R.Chief Financial Officer
- Erdogan-Trinkaus IpekChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
ETON Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$24.3M↑ +40.4%
Diluted EPS$0.05↓ -183.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $39,000.00 | $21.8M | $21.3M | $31.6M | $39.0M | $80.0M |
| Gross profit | -$397,000.00 | $19.0M | $14.3M | $21.1M | $23.4M | $42.7M |
| Operating income | -$27.1M | -$1.5M | -$8.3M | -$1.2M | -$2.6M | -$844,000.00 |
| Net income | -$28.0M | -$2.0M | -$9.0M | -$936,000.00 | -$3.8M | -$4.6M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$22.3M | -$4.7M | $4.8M | $6.8M | $969,000.00 | $10.5M |
| Free cash flow | -$22.4M | -$4.7M | $4.8M | $6.8M | $943,000.00 | $10.2M |
| Gross margin | -1017.9% | 87.1% | 67.4% | 66.6% | 60.0% | 53.5% |
| Operating margin | -69515.4% | -6.8% | -38.9% | -3.8% | -6.7% | -1.1% |
| Net margin | -71717.9% | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.1M | $10.3M | $11.6M | $17.3M | $18.9M | $22.5M | $21.3M | $24.3M |
| Gross profit | $5.6M | $6.3M | $6.5M | $9.9M | $11.9M | $7.9M | $13.1M | $14.7M |
| Operating income | -$2.9M | $509,000.00 | $629,000.00 | -$470,000.00 | -$1.5M | -$1.4M | $2.5M | $2.4M |
| Net income | -$3.0M | $627,000.00 | -$598,000.00 | -$1.6M | -$2.6M | -$1.9M | $1.5M | $1.6M |
| Diluted EPS | -$0.12 | $0.02 | — | -$0.06 | — | -$0.07 | — | $0.05 |
| Operating cash flow | $1.3M | $3.0M | -$765,000.00 | $2.1M | $8.0M | $12.0M | -$11.6M | $7.4M |
| Free cash flow | $1.3M | $3.0M | -$777,000.00 | $2.1M | $8.0M | $11.7M | -$11.6M | $7.3M |
| Gross margin | 62.0% | 61.0% | 55.6% | 57.1% | 63.0% | 35.0% | 61.6% | 60.7% |
| Operating margin | -32.3% | 4.9% | 5.4% | -2.7% | -7.8% | -6.1% | 11.6% | 9.9% |
| Net margin | -33.5% | 6.1% | -5.1% | -9.1% | -13.7% | -8.6% | 7.0% | 6.4% |
Company news
Jul 20, 2026
Jul 17, 2026
May 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | Opaleye Management Inc. | Sale | 15,000 | $37.54 | $563,146.50 | filing |
| 2026-07-14 | Opaleye Management Inc. | Sale | 15,000 | $37.54 | $563,146.50 | filing |
| 2026-07-14 | Opaleye Management Inc. | Sale | 13,315 | $37.54 | $499,886.38 | filing |
| 2026-07-14 | Opaleye Management Inc. | Sale | 13,315 | $37.54 | $499,886.38 | filing |
| 2026-07-14 | BRYNJELSEN SEAN· President & CEO | Option exercise | 200,000 | $1.37 | $274,000.00 | filing |
| 2026-07-12 | Krempa David· Chief Business Officer | Option exercise | 10,000 | — | — | filing |
| 2026-07-12 | BRYNJELSEN SEAN· President & CEO | Option exercise | 27,500 | — | — | filing |
| 2026-07-07 | Opaleye Management Inc. | Sale | 20,000 | $38.37 | $767,456.00 | filing |
| 2026-07-07 | Opaleye Management Inc. | Sale | 6,685 | $38.37 | $256,522.17 | filing |
| 2026-07-06 | Opaleye Management Inc. | Sale | 10,000 | $38.00 | $380,000.00 | filing |
| 2026-07-02 | Opaleye Management Inc. | Sale | 65,000 | $37.39 | $2.4M | filing |
| 2026-07-02 | Opaleye Management Inc. | Sale | 25,000 | $37.39 | $934,627.50 | filing |
| 2026-06-17 | Adams Jennifer McKie | Sale | 50,000 | $32.48 | $1.6M | filing |
| 2026-06-17 | Adams Jennifer McKie | Option exercise | 50,000 | $3.78 | $189,000.00 | filing |
| 2026-05-28 | BRYNJELSEN SEAN· President & CEO | Sale | 119,852 | $31.88 | $3.8M | filing |
| 2026-05-28 | BRYNJELSEN SEAN· President & CEO | Sale | 148 | $32.67 | $4,835.16 | filing |
| 2026-05-27 | Krempa David· Chief Business Officer | Sale | 19,679 | $31.47 | $619,374.88 | filing |
| 2026-05-27 | Krempa David· Chief Business Officer | Option exercise | 7,203 | $3.58 | $25,786.74 | filing |
| 2026-05-27 | Krempa David· Chief Business Officer | Option exercise | 12,476 | $1.37 | $17,092.12 | filing |
| 2026-05-26 | Krempa David· Chief Business Officer | Sale | 37,524 | $31.49 | $1.2M | filing |
| 2026-05-26 | Krempa David· Chief Business Officer | Option exercise | 25,000 | $1.38 | $34,500.00 | filing |
| 2026-05-26 | Krempa David· Chief Business Officer | Option exercise | 12,524 | $1.37 | $17,157.88 | filing |
| 2026-05-22 | Krempa David· Chief Business Officer | Sale | 32,963 | $33.22 | $1.1M | filing |
| 2026-05-22 | Krempa David· Chief Business Officer | Sale | 9,315 | $33.88 | $315,594.06 | filing |
| 2026-05-22 | Krempa David· Chief Business Officer | Option exercise | 30,591 | $3.58 | $109,515.78 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.